If you are searching for the atos share price, you might be met with highly conflicting data. On one screen, you might see a stock trading around €40 on the Euronext Paris; on another, a stock trading near $5 on the NASDAQ. This is because the search query for 'atos share price' represents one of the most common points of confusion in the financial markets: a tale of two entirely distinct companies sharing similar names or tickers.

In this comprehensive analysis, we will untangle this ticker confusion by examining both companies. First, we look at Atos SE (Euronext Paris: ATO.PA), the French multinational information technology giant currently navigating a historic corporate turnaround. Second, we explore Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage US biopharmaceutical company developing groundbreaking breast cancer therapies. By the end of this guide, you will understand exactly which stock you are looking at, their current financial standings in 2026, and their respective paths forward.

Atos SE (Euronext Paris: ATO.PA): The European IT Restructuring Story

For European tech investors, the atos share price has been a rollercoaster of extreme volatility, massive restructuring, and severe shareholder dilution. To understand where Atos SE stands today in 2026, we must look at the structural crises that brought the French IT heavyweight to its knees, and the aggressive measures taken to save it from bankruptcy.

The Path to Distress: Debt, Divestitures, and Delays

Historically, Atos SE was a crown jewel of the European technology sector. It managed critical IT infrastructure for the French government, handled cybersecurity for the European Commission, and acted as the primary digital partner for the Olympic Games. However, a series of debt-fueled acquisitions under previous management, coupled with a failure to rapidly transition its traditional managed infrastructure services (Tech Foundations) to the public cloud, left the company with a massive, unsustainable debt burden.

Between 2022 and 2024, the company attempted several restructuring schemes. It sought to split itself into two separate publicly traded entities: Tech Foundations (legacy IT outsourcing) and Eviden (cybersecurity, cloud, and supercomputing). High-profile deals to sell these divisions to external buyers—such as Czech billionaire Daniel Kretinsky's EP Equity Investment (EPEI) and European aerospace giant Airbus—continually collapsed. As its cash reserves dwindled and debt maturities loomed, the company's financial survival was thrown into serious doubt, driving the pre-split share price down to mere fractions of a cent.

The Accelerated Safeguard Plan and Shareholder Dilution

In late 2024, Atos SE entered an accelerated safeguard procedure under the supervision of French courts. This judicial restructuring framework brought together major bank creditors and bondholders to implement a massive debt-to-equity swap.

While this restructuring successfully wiped billions of euros of debt off Atos's balance sheet and secured its immediate survival, it came at a catastrophic cost to existing retail shareholders. The massive issuance of new shares to creditors diluted the existing equity pool by over 99%. For legacy investors, the value of their holdings was almost entirely wiped out, leaving a share capital consisting of tens of billions of hyper-diluted 'penny shares' trading at values below €0.01.

The 2025 Reverse Stock Split: Mechanics and Institutional Impact

Following the completion of its painful financial restructuring, Atos SE's share structure was highly fragmented. The stock was plagued by extreme volatility, driven by day-traders and high-frequency algorithms trading fractions of a penny. To restore credibility and normal trading dynamics, the Atos Board of Directors authorized a massive reverse stock split.

The Mechanics of the Split

On April 24, 2025, Atos SE completed a historic 10,000-to-1 reverse stock split. The mechanics of the transaction were straightforward but dramatic:

• Exchange Ratio: Shareholders exchanged 10,000 'old' ordinary shares (with a par value of €0.0001) for 1 'new' ordinary share (with a par value of €1.00).
• ISIN Change: The old ISIN code (FR0000051732) was retired, and the consolidated shares began trading under the new ISIN code FR001400X2S4 on Euronext Paris.
• Mechanical Price Correction: The transaction was a purely technical adjustment. Because the number of outstanding shares was divided by 10,000, the share price was mechanically multiplied by 10,000. For example, a shareholder who held 30,000 shares worth €0.0049 each (totaling €147) suddenly held 3 shares priced at €49 each (totaling €147).

Market Impact and Post-Split Performance

While reverse stock splits do not change a company's fundamental market capitalization or intrinsic value, they are vital for institutional investment. Many mutual funds and institutional managers have strict mandates preventing them from buying stocks trading below a certain threshold (often €1 or $5). By consolidating the shares and pushing the price back into the double digits, Atos SE regained entry to a broader pool of institutional capital.

Since the completion of the split, the atos share price has traded in a wide range between €35 and €60, reflecting the market's evolving sentiment on the progress of its operational turnaround. As of mid-2026, the share price has stabilized around the €42 mark, reflecting a market capitalization of approximately €710 million.

The 'Genesis' Strategic Plan: Rebuilding Atos SE from the Ground Up

Now operating under a secure capital structure, Atos SE is executing its four-year transformation and strategic plan, dubbed 'Genesis.' Led by Chairman and CEO Philippe Salle, the Genesis plan focuses on operational discipline, radical cost-cutting, and transitioning the group into an AI-first technology partner of choice.

Turnaround Progress: 2025 Financial Results

Atos's full-year 2025 financial results, released in March 2026, demonstrated that the company is meeting or exceeding its operational stabilization goals:

• Revenue: Group revenue reached €8,001 million, indicating a clear stabilization in organic growth trajectory, particularly in the fourth quarter.
• Profitability: Operating margin rose to €351 million (4.4% of revenue), which represents a doubling of profitability year-on-year.
• Headcount Optimization: As part of the Genesis cost-rationalization program, Atos reduced its global headcount by 19% to 63,193 employees, aligning its delivery capabilities with current contract demand.
• Liquidity and Balance Sheet: Atos ended 2025 with a healthy liquidity position of €1,705 million and restored its equity into positive territory, thanks to the successful execution of its financial restructuring.

A Gradual Start to 2026

In April 2026, Atos reported its Q1 2026 performance, showcasing a gradual but steady path forward. The company generated revenues of €1,739 million (€1,640 million at the go-forward perimeter). While organic growth was down approximately 11% at the go-forward perimeter—largely due to the deliberate exit from low-margin legacy contracts—the underlying commercial engine showed strong signs of restarting.

The Q1 2026 book-to-bill ratio reached 87% (with the Atos Strategic Business Unit at 89%), representing a solid increase compared to the prior year. Additionally, the company completed the sale of its Bull Advanced Computing activities on March 31, 2026, which injected €252 million of fresh cash flow, leaving the group with a robust liquidity pool of €1,736 million at the end of the quarter.

The Road to 2028: Bold Financial Ambitions

Under Philippe Salle's leadership, the long-term goals of the Genesis plan remain ambitious and clear:

1. Revenue Growth: Target group revenues of €9-10 billion by 2028.
2. Operating Margins: Accelerate margins to approximately 10% by 2028.
3. Deleveraging: Reduce net leverage to less than 1.5x operating income, with the ultimate goal of reclaiming an investment-grade credit rating profile.
4. Technological Pivot: Rapidly scale artificial intelligence services. Atos has launched several 'Sovereign Agentic Studios' across France, Germany, the UK, and the US to assist corporate clients in deploying agentic AI systems securely.

Atossa Therapeutics (NASDAQ: ATOS): The US Biotech Alternative

If the atos share price you are tracking is quoted in US dollars and fluctuates in the single digits (currently around $4.96), you are actually looking at Atossa Therapeutics, Inc. (NASDAQ: ATOS). This is a completely separate, US-based clinical-stage biopharmaceutical company focused on oncology.

Core Pipeline: The Promise of (Z)-Endoxifen

Atossa's investment thesis is almost entirely driven by its proprietary drug candidate, (Z)-Endoxifen.

Endoxifen is an active metabolite of tamoxifen, which has been the gold standard for breast cancer prevention and treatment for decades. However, tamoxifen must be metabolized by the liver's CYP2D6 enzyme to become active, and many women are 'poor metabolizers' who do not receive full therapeutic benefits. Atossa's oral (Z)-Endoxifen bypasses this liver metabolism pathway, delivering high, consistent drug concentrations directly to the patient.

Atossa has made significant clinical progress, presenting highly promising data at major oncology conferences, including the American Society of Clinical Oncology (ASCO) 2026 annual meeting. The drug is currently undergoing phase 2 and phase 3 clinical trials, specifically targeting:

• Patients with high mammographic breast density (MBD).
• Women diagnosed with ductal carcinoma in situ (DCIS).
• Premenopausal women with ER+/HER2- breast cancer (the EVANGELINE study).

Financial Position and Valuation

Unlike many early-stage biotech companies that carry heavy debt, Atossa Therapeutics boasts an exceptionally clean balance sheet. As of mid-2026, the company is debt-free and holds a robust cash reserve, giving it a strong financial strength rating of 9/10 according to analysts. This cash runway is crucial because it allows Atossa to fund its ongoing clinical trials without the immediate threat of dilutive secondary offerings.

However, because Atossa is a clinical-stage firm, it currently has no commercialized products and generates zero revenue. This explains its low profitability score and why the stock is highly speculative. Its valuation—currently sitting at a market capitalization of around $44 million—is entirely tied to the probability of (Z)-Endoxifen receiving FDA approval over the next few years.

Side-by-Side Comparison: Which 'ATOS' is in Your Portfolio?

To help you easily distinguish between these two companies, here is a detailed, side-by-side breakdown of their core metrics as of May 2026:

Investment Analysis: Risks, Opportunities, and Key Takeaways

Both companies offer compelling, albeit vastly different, risk-reward profiles for active investors.

Atos SE: The Turnaround Play

• The Opportunity: Atos SE represents a classic distressed turnaround story. If CEO Philippe Salle successfully executes the Genesis plan and achieves the 2028 targets (10% operating margins and €9-10B in revenues), the stock is significantly undervalued at its current €710 million market cap. Reclaiming an investment-grade credit rating would act as a powerful catalyst for the share price.
• The Risks: Restructuring a massive IT services provider is incredibly difficult. Transitioning legacy contracts, keeping highly skilled IT staff from migrating to competitors, and navigating a sluggish European enterprise spending environment present significant headwinds. Any delay in margin improvement or contract retention could send the stock lower.

Atossa Therapeutics: The Binary Biotech Bet

• The Opportunity: For risk-tolerant biotech investors, Atossa represents a pure-play bet on a potential blockbuster breast cancer therapy. The clinical data for (Z)-Endoxifen has been highly encouraging, and the company has the cash runway to see its trials through without immediate dilution.
• The Risks: Clinical-stage biotech investing is highly binary. If (Z)-Endoxifen fails to meet its primary endpoints in upcoming phase 3 readouts, or if the FDA raises regulatory hurdles, the stock could lose the vast majority of its value overnight. Investors must be prepared for extreme volatility.

Frequently Asked Questions (FAQ) About the Atos Share Price

Why did the Atos SE share price suddenly increase in April 2025?

Atos SE's share price did not increase due to a change in fundamental company valuation. Rather, it completed a 10,000-to-1 reverse stock split on April 24, 2025. This technical adjustment consolidated every 10,000 fractional penny shares into 1 new share with a par value of €1.00, mechanically multiplying the trading price by 10,000.

What is the current ISIN code for Atos SE shares?

Following the reverse stock split in 2025, Atos SE shares trade on Euronext Paris under the new ISIN code FR001400X2S4 (Ticker: ATO.PA).

Is Atos SE the same as Atossa Therapeutics?

No. They are completely different companies. Atos SE is a French IT consulting and services giant listed on Euronext Paris. Atossa Therapeutics is a US clinical-stage biopharmaceutical firm listed on the NASDAQ that develops breast cancer treatments. They are frequently confused because Atossa's ticker is ATOS, while Atos SE is often referred to as 'Atos.'

What are the main goals of Atos's 'Genesis' transformation plan?

The 'Genesis' plan aims to return Atos SE to sustainable, profitable growth by 2028. Key targets include achieving annual revenues of €9 to €10 billion, an operating margin of approximately 10%, a net debt leverage ratio below 1.5x, and securing an investment-grade credit profile.

Does Atos SE pay a dividend?

No. Atos SE does not currently pay a dividend. Following its massive debt restructuring and ongoing capital expenditure needs under the Genesis turnaround plan, all excess cash flow is being reinvested into business operations and debt reduction.

Conclusion: Tracking the Right Asset

Whether you are analyzing the turnaround of a legacy European tech provider or monitoring a clinical-stage biotechnology firm, understanding the clear distinction behind the atos share price is the first step toward making an informed investment decision.

For Atos SE, the worst of the liquidity crisis is over, and the focus has firmly shifted to operational execution under the Genesis plan. For Atossa Therapeutics, the path forward is paved with clinical trials and regulatory milestone updates for (Z)-Endoxifen. By keeping these two distinct assets separate in your market research, you can accurately track their charts, news, and fundamentals to align with your overall investment strategy.